We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Brain Tumors May Derive from Brain Stem Cells

By Biotechdaily staff writers
Posted on 04 Jul 2002
Investigators have found that glioblastoma tumor cells derived from brain tumors of patients can maintain their stem cell properties and may be induced to differentiate under certain conditions in tissue culture. More...
Their study appears in the July 2002 issue of GLIA.

When excised glioma cells were grown in culture, they behaved like stem cells but exhibited abnormal growth. The stem cells and their progeny also contained genes that were different from the genes found in normal brain tissue, and some of these genes did not turn on as they do in normal cells.

"Our observations suggest it is possible that tumor formation occurs when stem cells originating in a particular part of the brain--which continually divide and regenerate--go too far in the process of reproduction,” said Dr. Dennis Steindler from the Departments of Neuroscience and Neurosurgery at the University of Florida (Gainesville, USA).

"In recent years, it has been theorized that there may be a connection between brain tumors and stem cells,” Dr. Steindler said. "We believe we have the first evidence this is true, and that it starts with stem cells that may have been produced in the region we call the brain marrow, near the brain's central core and the fluid-filled ventricles. It appears that brain marrow stem cells home to an area where the brain is trying to repair itself, but while doing so--because these cells have to repopulate themselves to carry out the healing mission--may go too far and produce tumors.”

The researchers say the findings could lead to new treatments that would rehabilitate the errant cells by redirecting their normal growth into a more controlled pattern, rather than by killing the malignant cells, as current treatments are intended to do.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
HPV Test
Allplex HPV28 Detection
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Laboratory specialists and clinicians from 48 countries participated in this survey. Countries are indicated in red. (Omosule, Catherine L., Lang, Tim, Geaghan, Sharon M., et al. Mapping pediatric cardiac troponin testing worldwide: results from the IFCC survey on emerging applications, standardization needs and access. Chemistry and Laboratory Medicine (CCLM), 2026. https://doi.org/10.1515/cclm-2026-0711)

Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals

Cardiac troponin is released into the blood when heart muscle is damaged and is widely used as a rapid marker of cardiac injury in adults. In children, interpreting troponin results remains difficult because... Read more

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.